Enlivex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on November 17, 2020, covers the month of November 2020 for Enlivex Therapeutics Ltd., an Israeli company. The filing primarily announces a corporate governance change rather than financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a Board of Directors appointment and associated equity compensation.
Material Changes
The material change reported is the appointment of Dr. Brian Schwartz, M.D., to the Board of Directors on November 15, 2020. His term expires at the 2021 Annual Meeting of Shareholders. The filing confirms no related party transactions exceeding $120,000 have occurred since the beginning of the last fiscal year involving Dr. Schwartz.
Guidance, Outlook, and Compensation Details
There is no financial guidance or outlook provided in this filing. Regarding compensation, Dr. Schwartz will receive options to purchase an aggregate of 40,500 ordinary shares at an exercise price of $9.02 per share. These options have a ten-year term and vest ratably over four years, commencing on the first anniversary of the grant date. He will also participate in standard non-employee director compensation arrangements.
Investor Verification Checklist
- Verify the vesting schedule and exercise price ($9.02) of the 40,500 options granted to Dr. Schwartz.
- Confirm the absence of undisclosed related party transactions involving the new director.
- Review the Company's 2020 Proxy Statement (Exhibit 99.1 to the May 19, 2020 Form 6-K) for details on standard non-employee director compensation.
- Check the press release dated November 17, 2020, for additional context on Dr. Schwartz's qualifications.